Skip to main content
MyDeficiencies

Oxandrolone

Anabolic-androgenic steroid (androstan derivative, 17-alpha-alkylated)

Also sold as Oxandrin.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Oxandrolone does not carry the classical enzyme-induction depletion machinery seen in anticonvulsants or rifampin: unlike most 17-alpha-alkylated oral steroids, it is only minimally hepatically metabolized, current FDA labeling documents no CYP450 induction or inhibition, and no gastrointestinal absorption-interference mechanism is described for the oral tablet. Pharmacokinetic data indicate roughly a third of an oral dose is excreted in urine as unchanged parent drug within 72 hours, with only minor hydroxylated and lactone-hydrolysis metabolites, which is the pharmacologic reason oxandrolone is favored over other oral anabolic steroids in patients with hepatic impairment despite carrying its own boxed hepatotoxicity warning. One rat study found oxandrolone induces male-pattern CYP450 isozymes in female rat liver, a sex-specific, species-specific finding with no confirmed human relevance. The genuine, drug-specific classical-nutrient signal here is not a depletion mechanism at all but an adverse lipid effect: oxandrolone's own boxed warning and at least four independent human intervention studies from the 1970s-80s consistently document a substantial, reversible fall in HDL cholesterol (up to 36% in one trial), graded red here as a real, drug-specific, clinically meaningful finding, distinct from and in addition to the seven required physiological categories. A second real, drug-specific signal is androgen-class retention of sodium, chloride, water, potassium, calcium, and phosphate, bounded to higher doses and to patients with pre-existing cardiac, renal, or hepatic disease, exactly as documented in oxandrolone's own label.

Anabolic-androgenic steroid (androstan derivative, 17-alpha-alkylated) · ATC A14AA08 · also sold as Oxandrin and generic oxandrolone tablets · reviewed 2026-09-28. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Oxandrolone in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Lipid profile / HDL, substantial, reversible HDL-cholesterol decline

Red — Severe

Evidence in: Tier A

Oxandrolone reliably and substantially lowers HDL cholesterol, and can raise LDL cholesterol, in adults given the drug for hyperlipoproteinemia or catabolic-state indications. This is oxandrolone's best-evidenced classical adverse effect, quantified across multiple independent human intervention studies and named in its own boxed warning.

Full detail, limits and 5 references

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. RED · Tier A

Limits on what this shows

  • Null/negative findings: None identified contradicting the direction of effect; every oxandrolone-specific human study located in this review found the same HDL-lowering direction.
  • At-risk subgroups: Patients with pre-existing dyslipidemia or cardiovascular risk factors; higher-dose or longer-duration therapy; the label frames this as a class-wide atherosclerosis-risk concern.

Regulatory status

Boxed Warning, current FDA labeling: "BLOOD LIPID CHANGES...known to be associated with increased risk of atherosclerosis...DECREASED HIGH-DENSITY LIPOPROTEINS and sometimes increased LOW-DENSITY LIPOPROTEINS." Body text: "Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. These levels revert to normal on discontinuation of treatment."

Population evidence

Cheung et al. 1980, comparative human intervention study of four hypolipidemic drugs (Atherosclerosis, PMID 7362696): "During oxandrolone HDL cholesterol declined by 36 ± 20%." Olsson et al. 1974, human study of oxandrolone's effect on plasma lipoproteins and intravenous fat tolerance (Atherosclerosis, PMID 4360244). Tamai et al. 1979, human study of oxandrolone in patients with type IIa, IIb, and IV hyperlipoproteinemia (Artery, PMID 231951). Hara et al. 1981, human study of oxandrolone and triglyceride-rich/high-density lipoproteins (Artery, PMID 7316782). All four are oxandrolone-specific human intervention studies; full abstract text beyond the quoted Cheung finding could not be retrieved during this review (Semantic Scholar API rate-limited on repeated attempts for these older, pre-DOI-era citations), so effect sizes beyond the quoted 36% figure are not independently confirmed here and are not claimed.

Mechanism

Named at the class level: 17-alpha-alkylated oral androgens are understood to increase hepatic lipase activity, accelerating HDL-particle catabolism, and to reduce apolipoprotein A-I synthesis. A 1983 review of sex hormones and lipoprotein metabolism (De Gennes, Ann Endocrinol, PMID 6347027) discusses this class mechanism; oxandrolone-specific enzymatic confirmation was not independently retrieved in this review.

Counter-evidence held on record

The label states levels "revert to normal on discontinuation of treatment," meaning the effect is pharmacologic and reversible rather than a structural or permanent lipid-metabolism injury. This is a lipid-panel adverse effect requiring clinical monitoring, not a nutrient deficiency, and no dose of any nutrient corrects it. No supplement claim ("supports healthy cholesterol while on Anavar") is supported by any source located in this review; the appropriate response is lipid-panel monitoring and, where relevant, a prescriber's dose or duration adjustment, never self-directed supplementation.

Sodium, chloride, water, potassium, calcium, and phosphate retention, bounded to higher doses and pre-existing cardiac, renal, or hepatic disease

Orange — Moderate

Evidence in: Tier A

Oxandrolone's own labeling lists retention of sodium, chloride, water, potassium, phosphate, and calcium as an adverse reaction. This is a retention effect; supplementing any of these minerals would compound risk rather than correct a deficiency.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. ORANGE · Tier A

Limits on what this shows

  • Null/negative findings: None identified specific to this drug. A dedicated modern quantitative study at standard oxandrolone weight-restoration doses was not located.
  • At-risk subgroups: Pre-existing congestive heart failure, renal impairment (hyperkalemia risk compounds with potassium-sparing diuretics, ACE inhibitors/ARBs, or renal failure), hepatic impairment, and concomitant corticosteroid or ACTH therapy.

Regulatory status

Current FDA labeling, ADVERSE REACTIONS, Fluid and Electrolytes: "Edema, retention of serum electrolytes (sodium chloride, potassium, phosphate, calcium)." WARNINGS: "Edema with or without congestive heart failure may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease." Concomitant adrenal corticosteroids or ACTH are separately labeled to increase the edema risk.

Population evidence

A class-labeled effect drawn from long clinical experience with 17-alkylated androgen therapy. No modern, oxandrolone-specific RCT quantifying magnitude at standard weight-restoration doses was located in this review; the grade rests on regulatory-label authority (Tier A by definition), disclosed as such rather than as a quantified trial effect, consistent with how the equivalent finding was graded in this project's testosterone dossier.

Mechanism

Named at the class level: androgens have mineralocorticoid-adjacent activity promoting renal tubular sodium/water reabsorption, with secondary retention of potassium, calcium, and phosphate. Hypercalcemia is separately listed as an outright contraindication in patients with breast carcinoma or nephrosis, underscoring the retention direction.

Counter-evidence held on record

None found contradicting the retention direction. The absence of a modern quantitative human trial is a genuine evidence gap, noted here rather than treated as disconfirming. This is a retention/excess risk, not a deficiency. Never supplement sodium, potassium, calcium, or phosphate on the basis of this drug. In patients with renal impairment or on potassium-elevating drugs, potassium should be monitored, not replaced, and hypercalcemia is an outright contraindication in specific populations.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, oxandrolone-specific animal evidence of pathological cardiac remodeling; no human data

Yellow — Low

Evidence in: Tier B

One oxandrolone-specific rat study found both low and high doses promoted pathological cardiac remodeling. No human mitochondrial-structure or biogenesis data for this drug were identified.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · Tier B

Limits on what this shows

  • Null/negative findings: None identified; no human study of any kind was located for this category.
  • At-risk subgroups: Not established; the Ronchi study used young male rats, a population and species that may not generalize to adult human dosing patterns.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Ronchi et al. 2021, "Low and high doses of oxandrolone promote pathological cardiac remodeling in young male rats" (Steroids, PMID 33727119, DOI 10.1016/j.steroids.2021.108814): confirmed oxandrolone-specific rat model via Crossref and PubMed search-listing metadata. Full abstract text could not be retrieved during this review; Semantic Scholar API access for this specific paper returned HTTP 429 on repeated attempts, and no open-access full text was located. This entry is therefore built from the title and bibliographic record only, and the specific structural or mitochondrial parameters measured are not confirmed beyond "pathological cardiac remodeling" as stated in the title; this limitation is disclosed rather than filled in by inference. Adjacent class-level context: a broader androgen-receptor mitochondrial-biogenesis review (AJP Cell Physiol 2022, PMID 35704694) and a testosterone-specific mouse mitochondrial-biogenesis study (Usui et al. 2014, PMID 24726723) exist for testosterone, the reference androgen for this project, but oxandrolone was not in either cohort (Tier C for oxandrolone; see Overlap map).

Mechanism

Not established at the human level; not confirmed at the mechanistic level for the Ronchi rat study itself given the access limitation above. The class-level androgen-receptor mitochondrial-biogenesis literature is not consistently directional (some evidence points toward AR signaling promoting biogenesis; the Ronchi title points toward pathological remodeling), and this entry does not resolve that tension.

Counter-evidence held on record

The murine burn-model study cited under Oxidative stress below (Ahmad et al. 2019) found oxandrolone reduced, rather than increased, markers of organ injury and inflammation in heart and lung tissue in a different animal model (thermal injury rather than uninjured young rats), an apparently opposite direction from the Ronchi cardiac-remodeling finding. The two studies are not directly comparable (different injury models, different endpoints), and this tension is disclosed rather than resolved. This is animal-only, title-level evidence with an unresolved directional tension against a separate animal study. It is not a basis for either a human mitochondrial-harm claim or a mitochondrial-support supplement claim.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, mixed-direction animal evidence; no human data

Yellow — Low

Evidence in: Tier B, mixed direction

One oxandrolone-specific murine burn-injury study found reduced inflammatory and oxidative markers and improved organ protection; a separate oxandrolone-specific rat study found adverse pathological cardiac remodeling. No human oxidative-stress marker data for oxandrolone were identified.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · Tier B, mixed direction

Limits on what this shows

  • Null/negative findings: No human oxidative-stress marker (e.g., malondialdehyde, total antioxidant capacity) study for oxandrolone was located after multiple PubMed search phrasings, all returning zero results.
  • At-risk subgroups: Not established in humans. The protective finding is specific to the severe burn-injury context; it should not be generalized to oxandrolone use outside that catabolic-illness context.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Ahmad, Herndon & Szabo 2019, "Oxandrolone protects against the development of multiorgan failure, modulates the systemic inflammatory response and promotes wound healing during burn injury" (Burns, PMID 31018913, DOI 10.1016/j.burns.2018.10.006), murine burn model: full abstract retrieved via Semantic Scholar API. Findings included "significant amelioration of burn-induced accumulation of myeloperoxidase levels in heart and lung" (myeloperoxidase is a neutrophil-derived oxidative/inflammatory marker), reduced liver damage markers, protected hepatic and pancreatic function (renal function unaffected), significantly reduced TNF-alpha, IL-1alpha, IL-1beta, IL-4, IL-6, IL-10, IL-12, IP-10, G-CSF, GM-CSF, and interferon-gamma versus burn controls, and accelerated burn wound healing. Ronchi et al. 2021 (Steroids, PMID 33727119) found, by contrast, that both low and high oxandrolone doses promoted pathological cardiac remodeling in young male rats not subjected to burn injury; abstract access limitations for this study are disclosed under Mitochondrial burden above.

Mechanism

Not established as a unified mechanism. The Ahmad 2019 protective finding is consistent with oxandrolone's known anti-catabolic, anti-inflammatory profile in severe burn injury specifically; the Ronchi 2021 adverse finding suggests a separate, dose-independent cardiac effect in uninjured young animals. No single mechanism reconciles both.

Counter-evidence held on record

The two oxandrolone-specific animal findings point in different directions in different models; neither should be read as the definitive human-relevant answer, and this dossier does not resolve the tension for the reader. Animal-only, mixed-direction, and no human data exist. This is not a basis for a claim that oxandrolone "reduces oxidative stress" as a general wellness effect, nor for a claim that it requires antioxidant supplementation; see the separate Fails verification entry on NAC/TUDCA below.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron, no oxandrolone-specific evidence; class-level extrapolation from testosterone's hepcidin-suppression mechanism

Yellow — Low

See study details

No study measuring hepcidin, ferritin, or iron status in oxandrolone users was located after a genuine multi-channel search. The androgen-class mechanism, established for testosterone, is mechanistically plausible for oxandrolone as a fellow androgen-receptor agonist, but oxandrolone itself was not in any studied cohort.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · Tier C, class extrapolation

Limits on what this shows

  • Null/negative findings: None identified for oxandrolone specifically; this is an evidence gap rather than a negative trial.
  • At-risk subgroups: Not established for oxandrolone. By class-level analogy: patients with borderline iron stores, higher-dose therapy.

Regulatory status

Not addressed in oxandrolone's FDA labeling; the label does not mention iron, ferritin, hepcidin, erythropoiesis, or anemia at all (confirmed by full-text label search during this review).

Population evidence

Zero oxandrolone-specific results after PubMed searches for "oxandrolone hepcidin ferritin iron," "oxandrolone anemia hemoglobin," and "oxandrolone erythropoiesis red blood cell." Class-level (testosterone) evidence exists and was independently verified for this project's testosterone dossier: Bachman et al. 2010 (JCEM, PMID 20660052, RCT, n=109) found dose-dependent hepcidin suppression within one week of testosterone dosing; Bachman et al. 2014 (J Gerontol A Biol Sci Med Sci, PMID 24158761, RCT x6 months) and Artz et al. 2020 (JCEM, PMID 32785689, RCT substudy, n=95) both found hepcidin and ferritin decline with testosterone therapy, most pronounced in the first 1-3 months. Oxandrolone was not in any of these three cohorts; this is Tier C class extrapolation for oxandrolone, not Tier A/B drug-specific evidence.

Mechanism

Proposed at the class level only: androgen-receptor agonism suppresses hepatic hepcidin transcription, increasing iron availability for erythropoiesis. Whether oxandrolone, which does not aromatize to estradiol and has a distinct receptor-binding and metabolic profile from testosterone, produces the same magnitude of hepcidin suppression is not established.

Counter-evidence held on record

The complete absence of oxandrolone-specific iron/hepcidin literature, despite oxandrolone's decades of clinical and research use, is itself a mild counter-signal against a strong effect; if hepcidin suppression were as pronounced with oxandrolone as with testosterone, it would plausibly have been studied given oxandrolone's extensive use in catabolic/wasting research. This is class-level plausibility only, not a demonstrated oxandrolone effect. No iron supplementation is indicated on the basis of this entry; if anemia or unexplained fatigue is present, iron studies should be ordered and interpreted by a prescriber independent of this theoretical mechanism.

Copper, no evidence identified in either direction

Not graded — disclosed evidence gap

See study details

Copper, no evidence identified in either direction

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: Searched specifically against oxandrolone across PubMed search-listing pages ("oxandrolone copper," zero results; "anabolic androgenic steroid copper ceruloplasmin," zero results) and the Crossref REST API ("testosterone ceruloplasmin copper serum," ten results returned, none relating any androgen to ceruloplasmin or copper status). No drug-specific or class-level evidence at any tier was found for oxandrolone or for the androgen class generally, and no circulating consumer claim pairing oxandrolone or illicit "Anavar" use with copper depletion or excess was found in the course of this review (the zinc search below turned up only a burn-care "metabolic bundle" protocol that co-administers zinc alongside oxandrolone as routine burn nutrition support, not a claim that oxandrolone affects zinc or copper status). Both dual conditions for UNGRADED are met: no Tier B/C evidence, and no circulating claim to rebut as white. This mirrors the same ungraded finding for testosterone, the reference androgen for this project, independently re-searched here rather than carried forward from that dossier.

Tooling note

The Europe PMC REST API and OpenAlex API, both of which might otherwise surface additional copper-related literature, were not accessible during this review (see the headline finding's access note for the full disclosure of which channels succeeded and which did not). A later revision should re-query those two channels directly for "oxandrolone AND copper" and "anabolic steroid AND ceruloplasmin" before treating this as a durable conclusion rather than a possible access gap.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, no oxandrolone-specific evidence; class-level extrapolation from testosterone

Yellow — Low

See study details

No study of oxandrolone's effect on gut microbiome composition was located after a genuine multi-channel search. A small testosterone pilot found modest, mixed compositional shifts; the mechanism proposed there is plausible, but untested, for oxandrolone.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · Tier C, class extrapolation

Limits on what this shows

  • Null/negative findings: None identified for oxandrolone specifically; the testosterone pilot itself found no significant alpha-diversity change and no species-level signal tied to treatment duration.
  • At-risk subgroups: Not established for oxandrolone.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Zero oxandrolone-specific results after PubMed searches for "oxandrolone gut microbiome microbiota," "anabolic androgenic steroid gut microbiota," and "oxandrolone intestinal bacteria." Class-level (testosterone) evidence exists and was independently verified for this project's testosterone dossier: Harris et al. 2024 (mSphere, DOI 10.1128/msphere.00557-24), prospective pilot, n=9 transgender individuals starting testosterone: modest beta-diversity shifts (R²=0.035, P=0.009), no significant alpha-diversity change, altered glutamate-metabolism gene abundance. Oxandrolone was not in this cohort; this is Tier C class extrapolation for oxandrolone.

Mechanism

Proposed at the class level only, from the testosterone pilot: androgen exposure may increase host intestinal glutamate absorption, altering substrate availability for glutamate-metabolizing gut microbes. Not tested for oxandrolone, and oxandrolone's distinct (non-aromatizing) receptor and metabolic profile means the mechanism's applicability is uncertain.

Counter-evidence held on record

The source pilot (n=9) is too small to generalize even for testosterone; extending it to oxandrolone by class analogy compounds that uncertainty further. This is class-level, small-sample, indirect evidence. It does not support a microbiome-depletion or probiotic-need claim for oxandrolone.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization, polycythemia risk, bounded to high-dose anabolic steroid therapy

Orange — Moderate

Evidence in: Tier A

Oxandrolone's own label requires periodic hemoglobin/hematocrit monitoring for polycythemia in patients receiving high-dose anabolic steroid therapy. This is a retention/excess-direction hematologic finding, not an oxygen-delivery deficiency.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. ORANGE · Tier A

Limits on what this shows

  • Null/negative findings: None identified specific to oxandrolone; the absence of a modern quantitative human trial is a genuine evidence gap, disclosed here rather than treated as disconfirming.
  • At-risk subgroups: Patients on higher/prolonged doses, per the label's explicit "high doses" qualifier; by extension, obstructive sleep apnea, smokers, and baseline hematocrit near the upper-normal range are plausible risk amplifiers by analogy to other androgens, though not stated in oxandrolone's own label.

Regulatory status

Current FDA labeling, PRECAUTIONS: Laboratory Tests: "Hemoglobin and hematocrit should be checked periodically for polycythemia in patients who are receiving high doses of anabolic steroids."

Population evidence

The grade rests on this single Tier A regulatory-label statement; a dedicated oxandrolone-specific human trial quantifying hematocrit or hemoglobin rise was not located after multiple PubMed search phrasings ("oxandrolone hematocrit," "oxandrolone polycythemia," "oxandrolone anemia hemoglobin," "oxandrolone erythropoiesis red blood cell"), all of which returned zero oxandrolone-specific results. This is disclosed as a single-source, label-authority grade rather than a quantified trial effect, which is why this entry is orange rather than red (red requires at least two independent Tier A sources).

Mechanism

Not separately named in oxandrolone's own label. The class-level mechanism for androgen-associated erythrocytosis, established for testosterone (erythropoietin stimulation and hepcidin suppression), is mechanistically plausible for any androgen-receptor agonist including oxandrolone, but oxandrolone-specific hepcidin/erythropoietin data were not located (see the separate Iron entry below, graded yellow on this same class-level basis).

Counter-evidence held on record

None identified. The finding rests on a single Tier A source (the label itself), disclosed as a limitation rather than reinforced by an independent trial. This is an excess/retention finding, not a deficiency, and is not evidence that oxandrolone "improves oxygen delivery" as a performance claim. No supplement or dietary intervention is indicated to manage this; periodic hemoglobin/hematocrit monitoring and, if elevated, a prescriber-directed dose adjustment are the appropriate response, never iron or erythropoiesis-supporting supplementation.

ATP production, no direct measurement in any species; class-level mitochondrial-biogenesis extrapolation only

Yellow — Low

See study details

No study measuring cellular ATP synthesis or flux in oxandrolone users, or in any animal model of oxandrolone exposure, was located. Oxandrolone does have real, drug-specific human evidence of improved muscle protein net deposition and amino acid utilization in catabolic illness, which is an adjacent anabolic finding, not an ATP-flux measurement, and is not used to inflate this grade.

Full detail, limits and 4 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · Tier C, class extrapolation

Limits on what this shows

  • Null/negative findings: None identified; this reflects an evidence gap rather than a negative trial.
  • At-risk subgroups: None identified.

Regulatory status

Not addressed in FDA labeling.

Population evidence

No direct ATP-flux study identified for oxandrolone after a PubMed search for "oxandrolone ATP energy metabolism" (zero results). Adjacent, but distinct, oxandrolone-specific human findings: Sheffield-Moore et al. 2000, "Combined effects of hyperaminoacidemia and oxandrolone on skeletal muscle protein synthesis" (Am J Physiol Endocrinol Metab, PMID 10662711); Tuvdendorj et al. 2011, "Long-term oxandrolone treatment increases muscle protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn injury" (Surgery, PMID 21333314). Both are cited at title level; full abstract text could not be retrieved during this review (Semantic Scholar API rate-limited on repeated attempts for both). These describe protein-synthesis/amino-acid-utilization outcomes, which are anabolic endpoints, not direct measurements of mitochondrial ATP synthesis, and per this protocol's rules are not treated as ATP-production evidence. The only ATP-adjacent mechanistic literature located is class-level: an androgen-receptor mitochondrial-biogenesis review (AJP Cell Physiol 2022, PMID 35704694) and a testosterone-specific mouse mitochondrial-biogenesis study (Usui et al. 2014, PMID 24726723), both independently verified for this project's testosterone dossier, neither with oxandrolone in the cohort.

Mechanism

Not established at the human level for this specific endpoint, for oxandrolone or for the androgen class generally; the class-level review itself states the precise molecular mechanisms of androgen-receptor effects on mitochondrial bioenergetics are not yet established.

Counter-evidence held on record

None specific; the entry is limited by absence of direct data at every tier, disclosed here rather than overstated by borrowing from the adjacent protein-synthesis literature. Do not present this as evidence oxandrolone "boosts ATP" or cellular energy production. The real, well-evidenced muscle-protein-synthesis finding in catabolic illness is a distinct clinical outcome and should not be relabeled as an ATP or mitochondrial-energy claim.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Oxandrolone ("Anavar") is liver-safe / has no real hepatotoxicity risk because it is the mildest oral steroid

    Where it comes from: Bodybuilding and illicit-use forum content, and some supplement-marketing material contrasting oxandrolone favorably against other oral steroids

    Why it fails: Directly contradicted by oxandrolone's own current FDA labeling, which carries a Boxed Warning for peliosis hepatis (risk of life-threatening liver failure or intra-abdominal hemorrhage) and hepatocellular neoplasms, some malignant, plus body-text warnings of cholestatic hepatitis and jaundice at relatively low doses. A genuine nuance is disclosed rather than ignored: McCullough et al. 2007 (J Burn Care Res, DOI 10.1097/bcr.0b013e318053d257) found the incidence of hepatic dysfunction was statistically equivalent between oxandrolone-treated and control burn patients in that specific short-term population, suggesting the boxed-warning risks (peliosis hepatis, tumors) may be lower-frequency or longer-latency events than routine transaminase monitoring in a burn unit would detect, not that the risk is absent.

  • N-acetylcysteine (NAC) or TUDCA supplementation prevents or reverses oxandrolone-induced liver injury

    Where it comes from: Bodybuilding "liver support stack" content sold alongside illicit oxandrolone use

    Why it fails: No oxandrolone-specific or class-level trial evidence testing NAC or TUDCA against anabolic-steroid hepatotoxicity was located in this review. The documented mechanism of 17-alpha-alkylated steroid-induced cholestasis is bile-transporter and nuclear-receptor mediated (Petrov et al. 2020, Arch Toxicol, PMID 31894354, studying the related steroid epistane: upregulated bile acid synthesis via CYP8B1 and nuclear-receptor cross-talk), not primarily an oxidative-stress mechanism that antioxidant supplementation would be expected to address.

  • Oxandrolone depletes zinc; zinc supplementation is needed to support recovery or "post-cycle therapy" after illicit use

    Where it comes from: Bodybuilding post-cycle-therapy content pairing zinc with anabolic steroid use generally

    Why it fails: The literature located tests the reverse direction, zinc's effect on endogenous testosterone production, not any androgen's effect on zinc status. The one oxandrolone-adjacent result found (Taha et al. 2019, GMS Interdiscip Plast Reconstr Surg DGPW, PMID 31815086) describes a burn-care "metabolic bundle" that administers zinc alongside oxandrolone as standard nutritional support, not a study of oxandrolone's effect on zinc levels. No source shows oxandrolone lowers zinc.

  • Extra calcium or vitamin D is needed to support bone health while using oxandrolone

    Where it comes from: General anabolic-steroid wellness/supplement content

    Why it fails: Contradicted by the drug's own data: oxandrolone's label lists hypercalcemia as an outright contraindication (in breast carcinoma and nephrosis) and lists calcium retention as an adverse reaction alongside sodium, chloride, potassium, and phosphate. Calcium supplementation on this basis would compound a labeled excess risk, not correct a deficiency. The label's bone-related content concerns accelerated bone-age maturation and compromised adult height in children, an outcome of androgen action on the growth plate, not a vitamin D or calcium deficiency.

All references used above
  1. OXANDRIN (oxandrolone tablet, USP) prescribing information. — FDA-approved labeling, DailyMed, setid f622616e-4c11-4149-bf00-5ea5ce97800b.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, code A14AA08 (oxandrolone), 2026 edition. — Reference index.
  3. PubChem Compound Summary for CID 5878, Oxandrolone. Metabolism/Metabolites section (citing Masse et al., urinary metabolite excretion study). — Aggregated pharmacology database entry.Accessed via the PUG-View REST API (JSON); the interactive compound page itself requires JavaScript and returned only metadata to direct fetch. The primary Masse et al. citation was not independently retrieved beyond this secondary source.
  4. Waskiewicz MJ, Choudhuri S, Vanderbeck SM, Zhang XJ, Thomas PE. Induction of "Male-Specific" Cytochrome P450 Isozymes in Female Rats by Oxandrolone. — Rat model, Tier B. Drug Metab Dispos. 1995. DOI 10.1016/s0090-9556(25)06830-8.Title/author/journal metadata retrieved via the Crossref API; full text and abstract not retrieved.
  5. Cheung MC, Albers JJ, et al. High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. — Human intervention study, four hypolipidemic drugs including oxandrolone. Atherosclerosis. 1980. PMID 7362696.Read via PubMed search-listing snippet, which quoted the key 36% HDL-decline finding directly; the PubMed abstract page itself renders via JavaScript and was not separately opened.
  6. Olsson AG, et al. Effects of oxandrolone on plasma lipoproteins and the intravenous fat tolerance in man. — Human intervention study. Atherosclerosis. 1974. PMID 4360244.Title/author/journal/PMID retrieved via PubMed search-listing page; full abstract not retrieved (Semantic Scholar API rate-limited on repeated attempts for this pre-DOI-era citation).
  7. Tamai T, et al. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia. — Human intervention study. Artery. 1979. PMID 231951.Title/author/journal/PMID retrieved via PubMed search-listing page; full abstract not retrieved.
  8. Hara T, et al. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins. — Human intervention study. Artery. 1981. PMID 7316782.Title/author/journal/PMID retrieved via PubMed search-listing page; full abstract not retrieved.
  9. De Gennes JL, et al. Sex hormones and metabolism of lipoproteins. — Narrative review, class-level mechanism context. Ann Endocrinol (Paris). 1983. PMID 6347027.Title-level only; full text not retrieved.
  10. Ahmad A, Herndon DN, Szabo C. Oxandrolone protects against the development of multiorgan failure, modulates the systemic inflammatory response and promotes wound healing during burn injury. — Murine burn model, Tier B, drug-specific. Burns. 2019;45(3):671-681. PMID 31018913. DOI 10.1016/j.burns.2018.10.006.Full abstract text retrieved via the Semantic Scholar Graph API. Unpaywall confirmed no open-access full-text version exists; full text itself was not opened.
  11. Ronchi SN, Wan Mass EMS, Dalla Bernardina NR, de Melo Junior AF, dos Santos WC, de Andrade TU, Brasil GA, Bissoli NS. Low and high doses of oxandrolone promote pathological cardiac remodeling in young male rats. — Rat model, Tier B, drug-specific. Steroids. 2021. PMID 33727119. DOI 10.1016/j.steroids.2021.108814.Title, authors, journal, and DOI confirmed via the Crossref API and PubMed search-listing page. Semantic Scholar API access for the abstract returned HTTP 429 on repeated attempts across this review; cited at title level only.
  12. Sheffield-Moore M, Wolfe RR, Gore DC, et al. Combined effects of hyperaminoacidemia and oxandrolone on skeletal muscle protein synthesis. — Human study, Tier A/B, drug-specific. Am J Physiol Endocrinol Metab. 2000. PMID 10662711.Title-level only via PubMed search-listing page; Semantic Scholar API abstract retrieval rate-limited on repeated attempts.
  13. Tuvdendorj D, Chinkes DL, Zhang XJ, et al. Long-term oxandrolone treatment increases muscle protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn injury. — Human pediatric burn study, Tier A, drug-specific. Surgery. 2011. PMID 21333314.Title-level only via PubMed search-listing page; abstract not retrieved.
  14. Porro LJ, Herndon DN, Rodriguez NA, et al. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. — Human pediatric RCT, drug-specific. J Am Coll Surg. 2012. PMID 22463890.Title-level only via PubMed search-listing page; Semantic Scholar API abstract retrieval rate-limited. Cited for context in the headline finding, not used to support any specific graded entry beyond what is stated.
  15. Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment. — Human pediatric study, drug-specific. Ann Surg. 2005. PMID 16135924.Title-level only via PubMed search-listing page; Semantic Scholar API abstract retrieval rate-limited. Cited for context in the headline finding, not used to support any specific graded entry beyond what is stated.
  16. McCullough MC, Namias N, Schulman C, et al. Incidence of Hepatic Dysfunction Is Equivalent in Burn Patients Receiving Oxandrolone and Controls. — Human burn-population study, drug-specific. J Burn Care Res. 2007. DOI 10.1097/bcr.0b013e318053d257.Title, authors, journal, and DOI retrieved via the Crossref API; full abstract not retrieved.
  17. Petrov PD, Fernandez-Murga L, Conde I, et al. Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes. — In vitro human hepatocyte study of a related steroid (epistane, not oxandrolone), Tier C class-mechanism context. Arch Toxicol. 2020. PMID 31894354.Title-level only via PubMed search-listing page; cited for class-level cholestasis-mechanism context in the Fails verification NAC/TUDCA entry, not as oxandrolone-specific evidence.
  18. Petrovic A, Vukadin S, Sikora R, et al. Anabolic androgenic steroid-induced liver injury: An update. — Narrative review, class-level, oxandrolone not confirmed in scope. World J Gastroenterol. 2022. PMID 36051334.Title-level only; Semantic Scholar API abstract retrieval rate-limited on repeated attempts, and a direct journal-site fetch (wjgnet.com) returned a server error. Not used to support any graded entry.
  19. Taha H, Steinke B, Fischer H, Malcharek MJ, Kremer T, Gille J. A "metabolic bundle" including Oxandrolone in optimising the metabolic status of severely burn injured patients: a retrospective analysis of the first 50 patients. — Retrospective burn-care protocol analysis. GMS Interdiscip Plast Reconstr Surg DGPW. 2019. PMID 31815086.Title-level only; cited only to show zinc is co-administered alongside, not studied as an effect of, oxandrolone in this protocol (Fails verification / Copper entries).
  20. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. — Testosterone-specific human RCT, n=109; independently verified for this project's testosterone dossier, re-cited here as Tier C class context (oxandrolone not in cohort). J Clin Endocrinol Metab. 2010. PMID 20660052.Cohort excluded oxandrolone; testosterone-specific, cited only as class-level context for the Iron and Oxygen delivery/utilization entries.
  21. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin. — Testosterone-specific human RCT x6 months; independently verified for this project's testosterone dossier, re-cited here as Tier C class context (oxandrolone not in cohort). J Gerontol A Biol Sci Med Sci. 2014. PMID 24158761.Cohort excluded oxandrolone; testosterone-specific, cited only as class-level context for the Iron entry.
  22. Artz AS, Stephens-Shields AJ, Bhasin S, et al. Markers of iron flux during testosterone-mediated erythropoiesis in older men with unexplained or iron-deficiency anemia. — Testosterone-specific human RCT substudy, n=95; independently verified for this project's testosterone dossier, re-cited here as Tier C class context (oxandrolone not in cohort). J Clin Endocrinol Metab. 2020. PMID 32785689.Cohort excluded oxandrolone; testosterone-specific, cited only as class-level context for the Iron entry.
  23. Harris RM, Pace F, Kuntz TM, et al. Testosterone treatment impacts the intestinal microbiome of transgender individuals. — Testosterone-specific human pilot, n=9; independently verified for this project's testosterone dossier, re-cited here as Tier C class context (oxandrolone not in cohort). mSphere. 2024;9(10):e00557-24. DOI 10.1128/msphere.00557-24.Cohort excluded oxandrolone; testosterone-specific, cited only as class-level context for the Gut microbiome risk entry.
  24. Role of androgens and androgen receptor in control of mitochondrial function [review]. — Narrative mechanistic review, predominantly animal/cell data; independently verified for this project's testosterone dossier, re-cited here as Tier C class context (oxandrolone not in cohort). Am J Physiol Cell Physiol. 2022. PMID 35704694.Cohort excluded oxandrolone; class-level review, cited only as context for the Mitochondrial burden and ATP production entries.
  25. Usui T, et al. Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone-induced body weight loss in male mice. — Mouse model, testosterone-specific; independently verified for this project's testosterone dossier, re-cited here as Tier C class context (oxandrolone not in cohort). FEBS Lett. 2014. PMID 24726723.Cohort excluded oxandrolone; testosterone-specific mouse study, cited only as context for the Mitochondrial burden and ATP production entries.